Cumberland Pharmaceuticals (NASDAQ:CPIX) Upgraded at Wall Street Zen

Cumberland Pharmaceuticals (NASDAQ:CPIX) was upgraded by Wall Street Zen to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

Shares of Cumberland Pharmaceuticals stock opened at $4.95 on Friday. The business’s 50 day moving average price is $3.01 and its 200 day moving average price is $3.20. The company has a market cap of $74.05 million, a price-to-earnings ratio of -20.63 and a beta of -0.53. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23. Cumberland Pharmaceuticals has a one year low of $1.85 and a one year high of $7.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 8.06% and a positive return on equity of 5.13%. The company had revenue of $8.29 million during the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of CPIX. XTX Topco Ltd purchased a new stake in Cumberland Pharmaceuticals during the second quarter worth approximately $34,000. Heron Bay Capital Management purchased a new stake in shares of Cumberland Pharmaceuticals during the 2nd quarter worth approximately $111,000. Two Sigma Investments LP boosted its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 5,326 shares in the last quarter. Bridgeway Capital Management LLC grew its position in shares of Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after buying an additional 4,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after acquiring an additional 27,980 shares in the last quarter. 15.51% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.